VNDA Earnings Date: Feb 10, 2027 (Estimated) — Vanda Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is VNDA's next earnings date?
Vanda Pharmaceuticals Inc. (VNDA) is expected to report Q4 2026 earnings on Wednesday, February 10, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.48 on revenue of $76.9M.
How did VNDA do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), Vanda Pharmaceuticals Inc. posted EPS of -$0.37 versus the -$0.68 estimate, a beat of 45.8%. Revenue was $69.8M against a $69.2M estimate. The stock's 1-day post-earnings move was +1.3%.
How much does VNDA stock move after earnings?
VNDA beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.0% (up or down) in the day after earnings.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
🤖 AI Earnings Analysis
Positive Phase 3 NEREUS data—vomiting fell to 43% from 58.5% on placebo—offers Vanda a differentiated opening in GLP-1 care. Q3 revenue rose 24% to $69.8 million, but losses persist.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | -0.68 | -0.37 | +45.75% | $69.8M | ✅ Beat | +1.25% | — | — |
| 2026-08-05 | Q2 2026 | -0.58 | -1.04 | -82.46% | $50.5M | ❌ Miss | +0.49% | +1.96% | +4.91% |
| 2026-05-06 | Q1 2026 | -0.66 | -0.82 | -24.24% | $51.7M | ❌ Miss | -14.11% | -13.58% | -18.95% |
| 2026-02-11 | Q4 2025 | -1.67 | -2.39 | -43.11% | $57.2M | ❌ Miss | -17.63% | -17.90% | +18.57% |
| 2025-10-29 | Q3 2025 | -0.40 | -0.38 | +5.00% | $56.3M | ✅ Beat | -20.15% | -17.93% | -0.92% |
| 2025-07-31 | Q2 2025 | -0.34 | -0.46 | -35.29% | $52.6M | ❌ Miss | -8.78% | -9.64% | +0.64% |
| 2025-02-13 | Q4 2024 | -0.14 | -0.08 | +42.86% | $53.2M | ✅ Beat | -5.96% | -5.74% | +8.09% |
| 2024-07-31 | Q2 2024 | -0.21 | -0.08 | +61.90% | $50.5M | ✅ Beat | -3.42% | -10.96% | -10.62% |
Showing last 8 quarters.